Study on Adagrasib, Pembrolizumab, and Chemotherapy vs. Placebo, Pembrolizumab, and Chemotherapy for Untreated Non-Squamous Non-Small Cell Lung Cancer with KRAS G12C Mutation

Inclusion Criteria

• Diagnosed with non-squamous non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation, confirmed by lab tests.
• Cancer must be advanced or has spread to other parts of the body.
• Must have at least one tumor that can be measured by a CT or MRI scan.
• Have not received any previous treatment for advanced or metastatic cancer.
• Not suitable for treatments like chemoradiation or complete surgical removal of the cancer.
• Can have brain metastases if they are not causing symptoms and do not need immediate treatment. Any untreated brain metastases must be 20 mm or smaller.
• Any level of PD-L1 expression is acceptable, as determined by specific lab tests.

Exclusion Criteria

• Have an active or known autoimmune or inflammatory disease.
• Have serious heart conditions that are not controlled, occurring within the last 6 months.
• Have poor bone marrow or liver function or abnormal heart rhythms.
• Taking medications that affect heart rhythm and cannot be changed before starting the study.
• Have received treatments targeting the KRAS G12C mutation before.
• Have other serious medical or mental health conditions that could increase risks during the study.
• Other specific criteria may apply as defined by the study protocol.